Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL7AP82 (Ribosomal protein L7a pseudogene 82) is classified as a processed pseudogene, meaning it originated by reverse transcription of an mRNA and subsequent integration into the genome, but does not produce a functional protein. Processed pseudogenes such as RPL7AP82 typically lack regulatory elements and do not participate directly in cellular function, although some pseudogenes in general may regulate their parental gene as non-coding RNAs. RPL7AP82 is related to the protein-coding gene RPL7A, which encodes a core component of the large ribosomal 60S subunit, but RPL7AP82 itself does not play a role in ribosome assembly, translation, or known disease pathways[1][3][8][10]. There is no evidence to consider RPL7AP82 a receptor, therapeutic target, enzyme, transporter, or transcription factor. Its primary scientific relevance is as a member of the large family of ribosomal protein pseudogenes present throughout the human genome[1][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7a pseudogene 82 (RPL7AP82).